Company intelligence / Profile preview

Fluger

Madison, Wisconsin, United Statesfluger.com ↗

Ownership: Private
Development stage: Other

Overview

FluGen’s lead candidate, M2SR, is a supra-seasonal, live single-replication intranasal flu vaccine. In clinical trials—including a challenge trial—M2SR demonstrated protection against infection and illness across seven years of influenza virus drift. The vaccine induces durable mucosal and systemic immunity with the potential to cover an entire flu season or longer. Early data also support its use as a vector platform for other respiratory diseases including COVID–19.

Therapeutic areas: Infectious Diseases
Modalities: Live attenuated virus vaccineVaccine (intranasal)
Industry: Biotech

Partnerships

Predictive Oncology Inc. – formulation collaboration to improve stability/shelf-lifeAcademic collaborations not specified but likely given university ties/founders’ backgrounds

Beyond the preview

Go deeper on Fluger.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fluger.

Explore the full profile